Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

Nadia Ovchinsky; Madeleine Aumar; Alastair Baker; Ulrich Baumann; Philip Bufler; Mara Cananzi; Piotr Czubkowski; Özlem Durmaz; Ryan T. Fischer; Giuseppe Indolfi; Wikrom Karnsakul; Florence Lacaille; Way Seah Lee; Giuseppe Maggiore; Philip Rosenthal; Mathias Ruiz; Étienne Sokal; Ekkehard Sturm; Wendy van der Woerd; Henkjan J. Verkade; Andrew Wehrman; Christine Clemson; Qifeng Yu; Quanhong Ni; Jessica Ruvido; Susan Manganaro; Jan P. Mattsson

doi:10.1016/s2468-1253(24)00074-8

Abstract

In patients with Alagille syndrome, cholestasis-associated clinical features can include high serum bile acids and severe pruritus that can necessitate liver transplantation. We aimed to evaluate the efficacy and safety of the ileal bile acid transporter inhibitor odevixibat versus placebo in patients with Alagille syndrome.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ovchinsky et al. (2024) studied this question.

synapsesocial.com/papers/68e6de6eb6db64358765a569 https://doi.org/10.1016/s2468-1253(24)00074-8

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

Abstract

Discussion

Cite This Study

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading